Psychedelic Therapy for Wellness Studies Retrospectively

This observational cohort study (n=100) aims to assess the efficacy of psychedelics, including psilocybin, MDMA, LSD, and ketamine, for improving measures of wellness.

The study is conducted by the Canadian Forces Health Services Centre Ottawa and started in July 2022, with an estimated completion date in August 2025. The primary objective is to measure self-reported treatment effects of psychedelics for non-recreational purposes, specifically to self-medicate and alleviate symptoms of suffering. The research follows a retrospective self-report study design, focusing on a composite score of patient global perception, pain, function, and mood as measures of wellness.

The study involves 50 non-active military participants aged 18 to 99, recruited based on self-reports of past psychedelic medicine use for therapeutic purposes in the last 3 years. The retrospective survey will collect data on demographics, medical history, indications for use, adverse events, and various outcome measures. Risks are considered minimal, participation is voluntary, and anonymity is maintained. The study aims to provide insights into emerging treatments and potentially improve the quality of care for patients with various types of suffering, including those in the Canadian Forces with high rates of comorbid pain and mental health issues.

Compound Psilocybin MDMA Ketamine DMT LSD
Country Canada
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.